BioPharma articles

Herbalife Ltd. (HLF) Update: Former FTC Commission Harbour Ready to Risk Neck For The Company, Says Confident About Company’s Products

Herbalife Ltd. (HLF) Update: Former FTC Commission Harbour Ready to Risk Neck For The Company, Says Confident About Company’s Products

After taking the post of Head of Compliance team for Herbalife Ltd. (NYSE:HLF), former FTC Chief was quite comfortable after a brief look at the company’s operations. Pamela Jones Harbour took the post with the troubled company, which is facing accusations of running a pyramid scheme. The appointment of the former FTC chief helped the

Actavis plc (ACT) Has A New Merger Plan for Allergan, Inc. (AGN)

After battling with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to avoid a takeover, Allergan, Inc. (NYSE:AGN) should prepare itself for a takeover possibility from Actavis plc (NYSE:ACT). According to the sources, Actavis is likely to approach Allergan for a potential merger. This is not the first time when Actavis plc (NYSE:ACT) has initiated similar efforts and

Latest Strategy in Valeant Pharmaceuticals Intl Inc (VRX) -Pershing- Allergan Inc (AGN) Negotiation – Raising Bid Price

What happens when the share price of a particular company jumps by $15? There is an increase in the overall value of the company and this happens to be the latest strategy employed by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Pershing to persuade Allergan Inc (NYSE:AGN) to give its nod to the merger. April, 2014,

Eli Lilly and Co (LLY), Apple Inc. (AAPL), Netflix, Inc. (NFLX): Top 3 Stocks of Weatherly Asset Management L. P.

Weatherly Asset Management L. P. has a 13F portfolio value of $232 million with healthcare as its largest investment area, as per its recent SEC 13F filing. Carolyn P. Taylor is the manager of the fund with Eli Lilly and Co (NYSE:LLY), Apple Inc (NASDAQ:AAPL), and Netflix, Inc. (NASDAQ:NFLX) as the top three holdings of

Herbalife Ltd. (HLF) Strenthens Its Compliance Team With New Significant Appointment

After coming under the scanner of the Federal Trade Commission for running a pyramid scheme, Herbalife Ltd. (NYSE:HLF) has appointed former FTC official to head its compliance department. Pamela Jones Harbour, FTC Commissioner during 2003 and 2010, is said to be the senior vice president of global member compliance and privacy team for the company.

Tekmira Pharmaceuticals Corporation (TKMR), BioCryst Pharmaceuticals, Inc. (BCRX), Sarepta Therapeutics Inc (SRPT) Lead Ebola Treatment Campaign

Ebola took the world by surprise leading to a huge loss of human lives in the Western Africa plateau. With no steady treatment available for the Ebola virus, pharmaceutical companies are trying every bit to devise a medical treatment for the disease. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Sarepta Therapeutics Inc (NASDAQ:SRPT) are

Galmed Pharmaceuticals Ltd (GLMD) Surged 37.8% After FDA Approval for Fast Track Designation of NASH Drug

It was an excellent day for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) with a 37.81 percent increase in its share prices closing at $8.93. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced that the biopharmaceutical has received fast track designation for its NASH treatment drug, Aramchol, from the FDA. Fast Track Designation is given to the drugs developed for the

GlaxoSmithKline plc (ADR) (GSK) Faces Fines Worth $489 Million, Former Head to Serve Jail time

Nearly after a year and a half, the Chinese authorities have released their verdict for GlaxoSmithKline plc (ADR) (NYSE:GSK), which was accused of bribing doctors to use their medicines. GlaxoSmithKline plc (ADR) (NYSE:GSK) would have to pay fines amounting to £297 million or $489 million to the Chinese government. The state news agency, Xinhua, further

Gilead Sciences, Inc. (GILD) Says Pancreatic Cancer Treatment, Simtuzumab, Failed to Meet Trial Goals in Phase II

Gilead Sciences, Inc. (NASDAQ:GILD), a biotech company, has announced unsatisfactory results from a study that was meant to establish the efficacy of simtuzumab in Pancreatic Cancer Treatment. The study, which was at phase II, involved adding 200 or 700 milligrams of simtuzumab to gemcitabine in a bid to establish whether that would substantially improve progression-free

Avanir Pharmaceuticals Inc (AVNR) Ratings Boost After Successful Trial Results

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is all set on the right path after the successful Phase II clinical trial results of AVP-923. Piper Jaffray, stock analysis firm, upgraded the rating of Avanir Pharmaceuticals to a “positive” with a target price of $17. The shares of Avanir Pharmaceuticals nearly doubled after the positive test result announcement. Another